Search

Pacific Biosciences of California Inc

Gesloten

SectorGezondheidszorg

1.14 -11.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.1400000000000001

Max

1.29

Belangrijke statistieken

By Trading Economics

Inkomsten

32M

-8.3M

Verkoop

-7.5M

37M

EPS

-0.12

Winstmarge

-22.258

Werknemers

485

EBITDA

33M

-5.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+83.08% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-40M

441M

Vorige openingsprijs

12.77

Vorige sluitingsprijs

1.14

Nieuwssentiment

By Acuity

50%

50%

156 / 340 Rangschikking in Healthcare

Pacific Biosciences of California Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2026, 23:01 UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

4 aug 2026, 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

3 aug 2026, 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

31 jul 2026, 19:46 UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

29 jul 2026, 16:06 UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

28 jul 2026, 16:12 UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

27 jul 2026, 19:06 UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

24 jul 2026, 22:31 UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

22 jul 2026, 18:01 UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

21 jul 2026, 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20 jul 2026, 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Peer Vergelijking

Prijswijziging

Pacific Biosciences of California Inc Prognose

Koersdoel

By TipRanks

83.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.38 USD  83.08%

Hoogste 3 USD

Laagste 1.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacific Biosciences of California Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

2

Buy

1

Hold

1

Sell

Sentiment

By Acuity

156 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat